From: "Minnie" <accumulate@decisionworks.co.uk>
To: <paliourg@iit.demokritos.gr>
Subject: Have You Ever Profited From a Small-cap?
Date: Fri, 1 Jul 2005 14:53:37 +0300
MIME-Version: 1.0
Content-Type: text/html;
	charset="iso-8859-7"
Content-Transfer-Encoding: quoted-printable
X-Priority: 3
X-MSMail-Priority: Normal
X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2900.2527

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<META HTTP-EQUIV=3D"Content-Type" CONTENT=3D"text/html; =
charset=3Dus-ascii">
<META NAME=3D"Generator" CONTENT=3D"MS Exchange Server version =
6.5.7036.0">
<TITLE>Have You Ever Profited From a Small-cap?</TITLE>
</HEAD>
<BODY>
<!-- Converted from text/plain format -->

<P><FONT SIZE=3D2>TUESDAY 06/28/05 Its moving already..<BR>
<BR>
EXCITING ISSUE PGCN.OB GET IN NOW!!!<BR>
<BR>
(OTC Ti.cker: PGCN.OB)<BR>
<BR>
Current Price $1.75<BR>
5-Day Target: $6<BR>
10-Day Target: $11<BR>
3-Month Target: $25-28 or Higher<BR>
<BR>
PRESS RELEASE<BR>
<BR>
Pingchuan Signed Market Research Consignment Agreement With Moscow Sing =
Sing<BR>
Co. Ltd<BR>
<BR>
Thursday June 23, 10:31 am ET<BR>
<BR>
<BR>
HARBIN, China, June 23 /Xinhua-PRNewswire/ -- Pingchuan Pharmaceutical =
Inc.<BR>
(OTC Bulletin Board: PGCN.OB - News; &quot;PINGCHUAN&quot;) announced =
today that<BR>
PINGCHUAN signed a market research consignment agreement with Moscow =
Sing<BR>
Sing Co. Ltd (&quot;SING SING&quot;).<BR>
<BR>
ADVERTISEMENT<BR>
<BR>
According to the agreement, SING SING authorized PINGCHUAN as its =
exclusive<BR>
partner to conduct market researches for business projects in P. R. =
China<BR>
(exclude Hong Kong, Macao and Taiwan). PINGCHUAN promises to =
accomplish<BR>
commercial market researches and deliver business plans for SING SING =
within<BR>
the valid period of the agreement. The co-operation with SING SING, =
will<BR>
bring in revenue of USD 200,000 for PINGCHUAN.<BR>
<BR>
HERE IS ANOTHER GOOD REASON TO LOOK AT PGCN.OB<BR>
<BR>
Pingchuan Pharmaceutical Inc. (&quot;PINGCHUAN&quot;) is a =
modernized<BR>
pharmaceutical manufacturer with first-class medical R&amp;D ability, =
pioneered<BR>
medicine products, and well-established marketing network. Since its<BR>
establishment, PINGCHUAN has focused its businesses on diabetes medicine =
and<BR>
its medical products. The products of PINGCHUAN include health care<BR>
products, varieties of medicine, as well as medical apparatus. Kang =
Da<BR>
Glycosuria Capsule is a successful product of PINGCHUAN for treating<BR>
diabetes, which was first developed in 1998 and introduced to the market =
in<BR>
2001. PINGCHUAN has well-established marketing network and sale =
branches,<BR>
which include about 180,000 retail pharmacies/drugstores across =
China,<BR>
agency network in major cities like Beijing, Shanghai, Guangzhou, and =
Xi'an,<BR>
special counter sale at drug chain stores in key regions, residence<BR>
community clinic sale and promotion, as well as internet marketing =
through<BR>
the company's website. The marketing network of PINGCHUAN covers more =
than<BR>
50% districts of China and exports to US, Japan, Russia, and =
south-eastern<BR>
Asia.<BR>
<BR>
<BR>
Sick of hedge funds and flippers getting all the great new issues? =
Most<BR>
s.tock brokers give out their new issues to their largest commission =
paying<BR>
clients---and if you trade through an online broker or discount<BR>
broker---good luck ever getting 1 share of a new issue.<BR>
<BR>
WELL ALL THAT IS CHANGING -- THIS IS AN ONLINE INTERNET IPO. IF YOU =
ARE<BR>
RECEIVING THIS EMAIL, YOU ARE AMONG THE FIRST PUBLIC INVESTORS TO KNOW =
ABOUT<BR>
PGCN.OB !!!!<BR>
<BR>
<BR>
<BR>
Remember the gains from our recent&nbsp; Strong B.uy&nbsp; =
recommendations...<BR>
<BR>
It is only a matter of time before it is released out into the =
investment<BR>
community and they take it to the moon..<BR>
<BR>
<BR>
<BR>
<BR>
</FONT>
</P>

</BODY>
</HTML>
